AstraZeneca On Bridging The Gap Between Accelerated Approval And HTA Requirements
Executive Summary
Health technology assessment agencies are struggling to evaluate drugs on the basis of evidence generated for early approvals, says AstraZeneca.
You may also be interested in...
Scottish HTA Body Prepares For ‘Conditional Yes’ On Certain New Drugs
Scotland’s HTA body, the Scottish Medicines Consortium, is about to embark on a new system allowing it to give a “conditional yes” to medicines for which data may be limited at the time of marketing authorization. At the same time, changes are being implemented to the system for allowing patient access to drugs that have not been recommended by the SMC.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.